Comi, G., Alroughani, R., Boster, A. L., Bass, A. D., Berkovich, R., Fernández, Ó., . . . CARE-MS I, C. I. (2019). Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Citación estilo ChicagoComi, Giancarlo, et al. Efficacy of Alemtuzumab in Relapsing-remitting MS Patients Who Received Additional Courses After the Initial Two Courses: Pooled Analysis of the CARE-MS, Extension, and TOPAZ Studies. 2019.
Cita MLAComi, Giancarlo, et al. Efficacy of Alemtuzumab in Relapsing-remitting MS Patients Who Received Additional Courses After the Initial Two Courses: Pooled Analysis of the CARE-MS, Extension, and TOPAZ Studies. 2019.